Trimeris Reports First Quarter 2010 FUZEON® Sales Results
14 Aprile 2010 - 11:00PM
Business Wire
Trimeris, Inc. (Nasdaq: TRMS) (“Trimeris”) today announced
worldwide net sales of FUZEON for the first quarter of 2010 were
$24.4 million, down 12 percent from $27.8 million in the first
quarter of 2009, and down 4 percent from $25.5 million in the
fourth quarter of 2009. Net sales of FUZEON in the U.S. and Canada
for the first quarter of 2010 were $7.2 million, down 28 percent
from $10.0 million in the first quarter of 2009, and down 20
percent from $9.0 million in the fourth quarter of 2010. Net sales
of FUZEON outside the U.S. and Canada for the first quarter of 2010
were $17.3 million, down 3 percent from $17.8 million in the first
quarter of 2009, and up 5 percent from $16.5 million in the fourth
quarter of 2009. All sales of FUZEON are recorded by F. Hoffmann-La
Roche Ltd., Trimeris' collaborative partner.
Trimeris plans to release its complete financial results for the
first quarter of 2010 in early May 2010.
Net FUZEON Sales
The table below presents net FUZEON sales by quarter beginning
in the first quarter of 2008:
(millions) 2010 Q1 Q2
Q3 Q4 Total U.S/Canada Net Sales
$ 7.2 Ex. U.S/Canada Net Sales
17.3 Global
Net Sales $ 24.4
Brazil Purchase* $ 7.8
2009 Q1
Q2 Q3 Q4 Total U.S/Canada Net Sales $
10.0 $ 9.7 $ 10.4 $ 9.0 $ 39.1 Ex. U.S/Canada Net Sales 17.8
19.4 19.4 16.5
73.1 Global Net Sales $ 27.8 $ 29.1 $ 29.8
$ 25.5 $ 112.2 Brazil Purchase* $ 7.1 $ 8.0 $ 7.8 $
7.6 $ 30.4
2008 Q1 Q2 Q3
Q4 Total U.S/Canada Net Sales $ 17.0 $ 16.1 $ 14.9 $
16.1 $ 64.2 Ex. U.S/Canada Net Sales 25.7 22.2
30.6 24.4 102.8 Global
Net Sales $ 42.7 $ 38.3 $ 45.5 $ 40.5 $
167.0 Brazil Purchase* - - $ 11.4 $ 10.0 $ 21.4
(numbers may not add due to rounding)
*included in Ex. U.S/Canada Net Sales and Global Net Sales
About Trimeris, Inc.
Trimeris, Inc. (Nasdaq: TRMS) is a biopharmaceutical company
engaged in the development and commercialization of novel
therapeutic agents for the treatment of viral disease. The core
technology platform of fusion inhibition is based on blocking viral
entry into host cells. FUZEON, approved in the U.S., Canada and
European Union, is the first in a new class of anti-HIV drugs
called fusion inhibitors. For more information about Trimeris,
please visit the Company's website at http://www.trimeris.com.
Trimeris Safe Harbor Statement
This document and any attachments may contain forward-looking
information about the Company's financial results and business
prospects that involve substantial risks and uncertainties. These
statements can be identified by the fact that they use words such
as "expect," "project," "intend," "plan," "believe" and other words
and terms of similar meaning. Among the factors that could cause
actual results to differ materially are the following: there is
uncertainty regarding the success of research and development
activities, regulatory authorizations and product
commercializations; we are dependent on third parties for the sale,
marketing and distribution of our drug candidates; the market for
HIV therapeutics is very competitive with regular new product
entries that could affect the sales of our products; the results of
our previous clinical trials are not necessarily indicative of
future clinical trials; and our drug candidates are based upon
novel technology, are difficult and expensive to manufacture and
may cause unexpected side effects. For a detailed description of
these factors, see Trimeris' Form 10-K filed with the Securities
and Exchange Commission on March 16, 2010, and its subsequent
periodic reports filed with the SEC.
Grafico Azioni Trimeris (NASDAQ:TRMS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Trimeris (NASDAQ:TRMS)
Storico
Da Set 2023 a Set 2024